Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with elevated pre-chemotherapy CA19-9 levels.

[1]  E. Nakakura,et al.  Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  T. Sato,et al.  Staging laparoscopy for pancreatic cancer using intraoperative ultrasonography and fluorescence imaging: the SLING trial. , 2020, The British journal of surgery.

[3]  A. Saiura,et al.  High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment. , 2020, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[4]  N. Sasahira,et al.  Neoadjuvant gemcitabine and nab‐paclitaxel for borderline resectable pancreatic cancers: Intention‐to‐treat analysis compared with upfront surgery , 2020, Journal of hepato-biliary-pancreatic sciences.

[5]  M. Yano,et al.  Clinical implications of the serum CA19-9 level in "biological borderline resectability" and "biological downstaging" in the setting of preoperative chemoradiation therapy for pancreatic cancer. , 2020, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[6]  Song-Cheol Kim,et al.  Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer , 2020, Journal of clinical medicine.

[7]  W. Helton,et al.  Sustained CA19-9 response to neoadjuvant chemotherapy in borderline resectable pancreatic cancer predicts progression and survival. , 2020, The oncologist.

[8]  R. Schulick,et al.  Neoadjuvant Treatment in Pancreatic Cancer , 2020, Frontiers in Oncology.

[9]  J. Kench,et al.  The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer , 2020, Annals of Surgical Oncology.

[10]  H. Zeh,et al.  Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma , 2020, Annals of Surgical Oncology.

[11]  J. Kinoshita,et al.  Neoadjuvant chemotherapy with gemcitabine-based regimens improves the prognosis of node positive resectable pancreatic head cancer. , 2019, Molecular and clinical oncology.

[12]  T. Ohtsuka,et al.  Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery , 2019, Annals of Surgical Oncology.

[13]  W. Harmsen,et al.  Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. , 2019, Annals of surgery.

[14]  T. Ishizawa,et al.  Three-Dimensional Fixation: Pathological Protocol Following Pancreaticoduodenectomy with Portal Vein Resection for Pancreatic Cancer , 2019, Journal of Gastrointestinal Surgery.

[15]  B. Erickson,et al.  Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. , 2020, Annals of surgery.

[16]  T. Ishizawa,et al.  Optimal Extent of Superior Mesenteric Artery Dissection during Pancreaticoduodenectomy for Pancreatic Cancer: Balancing Surgical and Oncological Safety , 2018, Journal of Gastrointestinal Surgery.

[17]  P. Hosein,et al.  Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX , 2018, AntiCancer Research.

[18]  H. Zeh,et al.  FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma , 2018, Annals of Surgical Oncology.

[19]  J. Windsor,et al.  International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. , 2017, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[20]  T. Strom,et al.  Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy , 2017, Acta oncologica.

[21]  Baojin Fu,et al.  Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy? , 2017, Journal of surgical oncology.

[22]  D. Jäger,et al.  Pancreatic Cancer Surgery: The New R-status Counts , 2016, Annals of surgery.

[23]  M. Wagner,et al.  CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma , 2017, European Radiology.

[24]  N. Sata,et al.  Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) , 2016, The Lancet.

[25]  M. Besselink,et al.  Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer , 2016, Annals of Surgical Oncology.

[26]  Z. Wainberg,et al.  CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer , 2016, Journal of Gastrointestinal Surgery.

[27]  A. Saiura,et al.  Pancreatoduodenectomy With Systematic Mesopancreas Dissection Using a Supracolic Anterior Artery-first Approach , 2015, Annals of surgery.

[28]  Jeffrey W. Clark,et al.  "Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer." , 2017, Annals of surgery.

[29]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[30]  J. Werner,et al.  CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy , 2013, Annals of Surgical Oncology.

[31]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[32]  Jeffrey E. Lee,et al.  Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. , 2008, Journal of the American College of Surgeons.

[33]  Jeffrey E. Lee,et al.  Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy , 2006, Annals of Surgical Oncology.

[34]  D. Finkelstein,et al.  Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Furuse,et al.  Primary tumor of pancreatic cancer as a measurable target lesion in chemotherapy trials. , 2005, Japanese journal of clinical oncology.

[36]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.

[37]  I Ihse,et al.  Influence of Resection Margins on Survival for Patients With Pancreatic Cancer Treated by Adjuvant Chemoradiation and/or Chemotherapy in the ESPAC-1 Randomized Controlled Trial , 2001, Annals of surgery.